Boston Scientific Corporation
General ticker "BSX" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $140.6B (TTM average)
Boston Scientific Corporation does not follow the US Stock Market performance with the rate: -30.4%.
Estimated limits based on current volatility of 3.5%: low 45.57$, high 48.84$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 48000 (+6.7%) as of 2023
- US accounted for 9.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Regulatory and compliance, Economic downturns and volatility, Cybersecurity threats, Litigation risks
- Current price 41.2% below estimated low
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [81.07$, 115.72$]
- 2026-12-31 to 2027-12-31 estimated range: [85.46$, 121.22$]
Financial Metrics affecting the BSX estimates:
- Negative: with PPE of 31.4 at the end of fiscal year the price was very high
- Positive: 7.54 < Operating profit margin, % of 18.00
- Positive: -0.02 < Operating cash flow per share per price, % of 3.20
- Positive: 42.59 < Shareholder equity ratio, % of 55.49 <= 64.29
- Positive: Return on assets ratio (scaled to [-100,100]) of 6.21 > 6.06
- Positive: Interest expense per share per price, % of 0.25 <= 0.73
- Negative: Investing cash flow per share per price, % of -1.86 <= -0.60
- Positive: Industry inventory ratio change (median), % of -0.30 <= -0.16
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
Short-term BSX quotes
Long-term BSX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $14,240.00MM | $16,747.00MM | $20,074.00MM |
| Operating Expenses | $11,897.00MM | $14,144.00MM | $16,461.00MM |
| Operating Income | $2,343.00MM | $2,603.00MM | $3,613.00MM |
| Non-Operating Income | $-358.00MM | $-321.00MM | $-228.00MM |
| Interest Expense | $265.00MM | $305.00MM | $349.00MM |
| R&D Expense | $1,414.00MM | $1,615.00MM | $2,052.00MM |
| Income(Loss) | $1,985.00MM | $2,282.00MM | $3,385.00MM |
| Taxes | $393.00MM | $436.00MM | $493.00MM |
| Net Income(Loss)* | $1,593.00MM | $1,854.00MM | $2,898.00MM |
| Stockholders Equity | $19,282.00MM | $21,770.00MM | $24,233.00MM |
| Inventory | $2,484.00MM | $2,810.00MM | $2,944.00MM |
| Assets | $35,136.00MM | $39,395.00MM | $43,673.00MM |
| Operating Cash Flow | $2,503.00MM | $3,435.00MM | $4,534.00MM |
| Capital expenditure | $800.00MM | $790.00MM | $876.00MM |
| Investing Cash Flow | $-2,574.00MM | $-5,687.00MM | $-2,640.00MM |
| Financing Cash Flow | $5.00MM | $1,814.00MM | $-395.00MM |
| Earnings Per Share** | $1.10 | $1.26 | $1.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.